Kinnate Biopharma, one of the biotechs working to tackle both problems, has raised $98 million to fund its plan to move two of its preclinical programs into the clinic next year. The Series C financing was led by RA Capital Management, a new backer.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,